NCT01506765View on ClinicalTrials.gov

Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

September 30, 2006

Conditions

Schizophrenia

Interventions

DRUG

N-Acetyl-Cysteine (NAC)

Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks

All Listed Sponsors

lead

Centre Hospitalier Universitaire Vaudois

OTHER